 Recurrence
"Recurrence" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The return of a sign, symptom, or disease after a remission.
| Descriptor ID |
D012008
|
| MeSH Number(s) |
C23.550.291.937
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recurrence".
Below are MeSH descriptors whose meaning is more specific than "Recurrence".
This graph shows the total number of publications written about "Recurrence" by people in this website by year, and whether "Recurrence" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 0 | 5 | 5 | | 1981 | 0 | 5 | 5 | | 1982 | 0 | 9 | 9 | | 1983 | 0 | 4 | 4 | | 1984 | 0 | 6 | 6 | | 1985 | 0 | 6 | 6 | | 1986 | 0 | 9 | 9 | | 1987 | 0 | 3 | 3 | | 1988 | 0 | 10 | 10 | | 1989 | 0 | 20 | 20 | | 1990 | 0 | 8 | 8 | | 1991 | 0 | 9 | 9 | | 1992 | 0 | 12 | 12 | | 1993 | 0 | 14 | 14 | | 1994 | 0 | 12 | 12 | | 1995 | 0 | 22 | 22 | | 1996 | 0 | 13 | 13 | | 1997 | 0 | 21 | 21 | | 1998 | 0 | 21 | 21 | | 1999 | 0 | 26 | 26 | | 2000 | 0 | 20 | 20 | | 2001 | 0 | 23 | 23 | | 2002 | 0 | 19 | 19 | | 2003 | 0 | 21 | 21 | | 2004 | 0 | 19 | 19 | | 2005 | 0 | 25 | 25 | | 2006 | 0 | 29 | 29 | | 2007 | 0 | 20 | 20 | | 2008 | 0 | 33 | 33 | | 2009 | 0 | 23 | 23 | | 2010 | 0 | 42 | 42 | | 2011 | 0 | 39 | 39 | | 2012 | 0 | 39 | 39 | | 2013 | 0 | 37 | 37 | | 2014 | 0 | 31 | 31 | | 2015 | 0 | 34 | 34 | | 2016 | 1 | 45 | 46 | | 2017 | 0 | 29 | 29 | | 2018 | 0 | 29 | 29 | | 2019 | 0 | 28 | 28 | | 2020 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Recurrence" by people in Profiles.
-
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 08 13; 383(7):617-629.
-
Paul JD, Cifu AS. Management of Acute Pulmonary Embolism. JAMA. 2020 Aug 11; 324(6):597-598.
-
Ahmed O, Yu Q, Paul J, Navuluri R, Funaki B, Van Ha T. Meta-Analysis of the Usefulness of Inferior Vena Cava Filters in Massive and Submassive Pulmonary Embolism. Am J Cardiol. 2020 08 01; 128:54-59.
-
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.
-
Coccaro EF, Lee RJ. Disordered Aggression and Violence in the United States. J Clin Psychiatry. 2020 03 17; 81(2).
-
Wallace A, Liu P, Cipriani NA, Ginat D, Portugal L. Pituitary Adenoma Deposit in the Nasolabial Region Following Sublabial Transsphenoidal Surgery in the Setting of Nelson Syndrome. J Craniofac Surg. 2020 Jan/Feb; 31(1):e68-e69.
-
Ritterhouse LL, Parilla M, Zhen CJ, Wurst MN, Puranik R, Henderson CM, Joudeh NZ, Hartley MJ, Haridas R, Wanjari P, Furtado LV, Kadri S, Segal JP. Clinical Validation and Implementation of a Measurable Residual Disease Assay for NPM1 in Acute Myeloid Leukemia by Error-Corrected Next-Generation Sequencing. Mol Diagn Ther. 2019 12; 23(6):791-802.
-
Lei DK, Ollech JE, Andersen M, Weisshof R, Zmeter N, Sossenheimer P, Rubin DT. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. Am J Gastroenterol. 2019 12; 114(12):1904-1908.
-
Jabbour E, Gökbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leuk Res. 2020 01; 88:106283.
-
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. N Engl J Med. 2019 10 31; 381(18):1728-1740.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|